Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Alto Neuroscience, Inc.NYSE: ANRO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $114.94M rose 1159.4% year over year, behind the +1517.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 129.0% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +1159.4% toward the trailing-twelve-month pace of +1517.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 60.08M USD
- Year-over-year change
- -55.7%
- 4-year CAGR
- +17.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.08M | -55.7% |
| FY2024 | 2024-12-31 | 135.69M | +99.2% |
| FY2023 | 2023-12-31 | 68.13M | +55.6% |
| FY2022 | 2022-12-31 | 43.79M | +38.2% |
| FY2021 | 2021-12-31 | 31.69M | — |
Financing Cash Flow vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1517.0% is the 3rd highest of 9, against a peer median of +15.7%.
- Over three fiscal years its annual growth of +11.1% compares with a peer median of -3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $365.04M USD | +52499.0% | +12.5% | — | |
| LTM Mar 2026 | $173.2M USD | +64727.2% | -4.7% | — | |
| LTM Mar 2026 | $165.89M USD | +1517.0% | +11.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $112.79M USD | +3.6% | — | — |
| LTM Mar 2026 | $88.73M USD | +27.9% | +236.4% | 2309.3% | |
| LTM Dec 2025 | $45.77M USD | — | -22.1% | — | |
| LTM Mar 2026 | $17.39M USD | -123.8% | — | 25.5% | |
| LTM Mar 2026 | $2.59M USD | +127.8% | +75.3% | 1.2% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| LTM Mar 2026 | $191.89K USD | -76.4% | -2.7% | — | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding ANRO) | — | +15.7% | -3.7% | 25.5% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M |
| Change in Working Capital | (572K) | 4.58M | (698K) | 4.06M | 33K |
| Accounts Receivables | (1.29M) | 1.16M | 325K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 458K | 1.01M | (632K) | 516K | 221K |
| Other Working Capital | 255K | 2.42M | (391K) | 3.54M | (188K) |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M |
| Operating Cash Flow | (9.26M) | (20.39M) | (33.45M) | (47.42M) | (51.77M) |
| Capital Expenditures | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Debt Repayment | 0 | 9.83M | 0 | 1.25M | 9.48M |
| Common Stock Issued | 7K | 43K | 181K | 137.58M | 50.7M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (167K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (205K) | (341K) | (2.05M) | (3.14M) | 67K |
| Financing Cash Flow | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M |
| Effect of Forex Changes | (50K) | (24K) | (8K) | (11K) | (30K) |
| Net Change in Cash | 21.7M | 22.64M | 34.2M | 86.18M | 8.26M |
| Free Cash Flow | (9.94M) | (21.13M) | (33.92M) | (49.5M) | (51.79M) |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.